Animal models for the preclinical testing of drugs against osteoporosis
Ammann, P.; Rizzoli, R.; Bonjour, J.P.
Revue du Rhumatisme 66(11): 532-533
1999
ISSN/ISBN: 1169-8446 PMID: 10591112 Document Number: 511158
Document emailed within 1 workday
Related Documents
Mosekilde, L. 1995: Assessing bone quality--animal models in preclinical osteoporosis research Bone 17(4 Suppl): 343s-352sOchi, H.; Takeda, S. 2011: Animal models for bone and joint disease. the genetically-modified mice as a tool for osteoporosis research Clinical Calcium 21(2): 226-232
Reddy, D.S. 1998: Preclinical and clinical behavioral paradigms for testing drugs that affect learning and memory processes Methods and Findings in Experimental and Clinical Pharmacology 20(3): 249-277
Erdô, F.; Hossmann, K.-A. 2007: Animal models of cerebral ischemia--testing therapeutic strategies in vivo Ideggyogyaszati Szemle 60(9-10): 356-369
Smith, M.M.; Little, C.B.; Rodgers, K.; Ghosh, P. 1997: Animal models used for the evaluation of anti-osteoarthritis drugs Pathologie-Biologie 45(4): 313-320
Ghosh, P.; Burkhardt, D.; Read, R.; Bellenger, C. 1991: Recent advances in animal models for evaluating chondroprotective drugs Journal of Rheumatology. Supplement 27: 143-146
Wascher, T.C.; Dittrich, P.; Kukovetz, W.R. 1991: Antiarrhythmic effects of two new propafenone related drugs. a study on four animal models of arrhythmia Arzneimittel-Forschung 41(2): 119-124
Hall, T.C. 1978: Steroid carriers of cytotoxic agents: evaluation of antineoplastic effects of drugs and animal models Cancer Treatment Reports 62(8): 1263-1264
Löscher, W. 1984: Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. a review Methods and Findings in Experimental and Clinical Pharmacology 6(9): 531-547
Miller, J.L. 1986: In vitro methods not likely to replace animal testing of drugs Clinical Pharmacy 5(5): 351; 354
Płaźnik, A.; Kostowski, W. 1991: The involvement of serotonin and noradrenaline in the psychopathological processes of stress and depression: animal models and the effect of antidepressant drugs Polish Journal of Pharmacology and Pharmacy 43(4): 301-322
Chen, C.; Fang, W. 2003: Advances in the study on animal models of ventricular hypertrophy and the effects of Chinese traditional drugs against ventricular hypertrophy Zhongguo Zhong Yao Za Zhi 28(4): 299-302
Pill, J.; Stegmeier, K.; Schmidt, F.H. 1990: Effects of drugs affecting cholesterol biosynthesis pathway on BM 15.766-induced 7-dehydrocholesterol accumulation in rats. An animal model for testing compounds reducing cholesterol synthesis Methods and Findings in Experimental and Clinical Pharmacology 12(3): 167-174
Heuer, H.O. 1991: The effects of hetrazepine PAF antagonists in preclinical models of asthma Agents and Actions. Supplements 34: 229-245
Hesse, D.; Knierim, U.; Borell Von, E.; Herrmann, H.; Koch, L.; Mueller, C.; Rauch, H.W.; Sachser, N.; Schwabenbauer, K.; Zerbe, F. 1999: Voluntary testing procedures of farm animal housing equipment according to the Animal Welfare Act of 1998 Deutsche Tierärztliche Wochenschrift 106(4): 138-141
Mashiba, T.; Iwata, K.; Komatsubara, S.; Manabe, T. 2011: Animal models for bone and joint disease. Animal fracture model and fracture healing process Clinical Calcium 21(2): 235-241
Gokhale, P.C.; Kotwani, R.N.; Dange, S.Y.; Kshirsagar, N.A.; Pandya, S.K. 1993: Preclinical & pharmaceutical testing of liposomal amphotericin B Indian Journal of Medical Research 98: 75-78
1988: The Veterinary Service Board. Animal drug legislation. Packaging and labelling of animal drugs Tijdschrift Voor Diergeneeskunde 113(18): 1031-1032
Tyers, G.F.; Foresman, R.A.; Park, C.D.; Lerner, E.H.; Torman, H.A.; Waldhausen, J.A. 1971: Preclinical testing of a redundant, rechargeable cardiac pacemaker Journal of Thoracic and Cardiovascular Surgery 62(5): 763-768
Hoffmeister, F.; Assmann, G.; Born, G.V.; Bühler, F.R.; Caspary, W.F.; Feldmann, R.J.; Siegenthaler, W. 1989: Panel discussion. II: Objectives of basic research and predictive value preclinical testing Arzneimittel-Forschung 39(8a): 1035-1040